Jim Cramer's Top Takeaways: Carnival, Alder Biopharmaceuticals, T-Mobile, Dish Network

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

CCL Chart
CCL data by YCharts

Carnival (CCL): In an exclusive interview, Cramer sat down with Arnold Donald, president and CEO of Carnival, the cruise operator that's staged a remarkable turnaround after a series of disasters including capsized ships, engine room fires and ebola scares.

Donald explained that Carnival's turnaround started with a remarkable company that aligned all nine of its brands around a common objective, giving their guests more than what they want. Once the problems were addressed, the challenge was to change the image of cruising, primarily through word mouth.

Donald also touted Carnival's 10th brand, Fathom, which is debuting with a single ship. Fathom introduces the concept of social impact cruising, sailing to a destination and doing some good while you're there. Fathom's destination is the Dominican Republic, where guests can volunteer in a variety of areas.

ALDR Chart
ALDR data by YCharts

Alder Biopharmaceuticals (ALDR): In his second interview, Cramer also sat down with Dr. Randall Schatzman, founder, president and CEO of Alder, a development-stage biotech working on two antibody therapies for chronic migraines and rheumatoid arthritis.

Schatzman explained that there are 36 million patients in the U.S. who suffer from migraines, which is debilitating and causes nausea, vomiting and light sensitivity. Alder's therapy targets the cause of migraines, preventing them from happening in the first place.

So far the treatment has been met with positive responses in Phase II trials, with nearly a third of patients experiencing zero migraines. Schatzman said the treatment is being tested as an IV infusion and a self-administered option.

Alder's rheumatoid arthritis treatment is in Phase I testing but is also proving to be favorable with more patients going into remission than the current leading treatments.

Given the gigantic unmet needs, Cramer said he sees why this stock is up 229% over the past year.

TMUS Chart
TMUS data by YCharts

T-Mobile (TMUS) and Dish Network (DISH): Where there's smoke, there's usually a fire, and these two stocks are smoldering.

Both T-Mobile and Dish stocks rallied higher today on the rumors that the two might be in merger talks. Cramer said the deal makes perfect sense. T-Mobile is a terrific wireless carrier but lacks wireless spectrum; Dish is a terrific TV operator that also happens to have a ton of available spectrum.

Put these two together and you'd have a wireless powerhouse with a TV kicker, Cramer noted. That's why the cellular tower stocks all rallied today in anticipation of a deal that would surely see T-Mobile rapidly building out its network capacity.

Neither company is commenting on the rumors, but Cramer concluded the deal would be a winner.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

More from Opinion

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook

PayPal Strikes Again, Facebook, and AT&T -- 3 Tech Stories You Must Know

PayPal Strikes Again, Facebook, and AT&T -- 3 Tech Stories You Must Know

How to Invest Like Warren Buffett

How to Invest Like Warren Buffett

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites

50 Stocks That Could Be Shredded If a U.S. Trade War With China Ignites